ASBM included in IHP article: Stakeholders gear up for biosimilar substitution battle in 2013

January 10, 2013 1:24 PM

 

Inside Health Policy’s “Stakeholders Gear Up For Biosimilar Substitution Battle In 2013” article includes mentions of ASBM and quotes Dr. Dolinar:

“Still, groups like the Alliance for Safe Biologic Medicines, which has a broad membership of patient groups and innovator biologic companies, are pressing for a unique naming scheme, saying it is pertinent for ensuring safety and tracking adverse events.

“‘[I]t is important to understand that biosimilar and interchangeable biological products will be only similar to, but not the same as, an original reference product. From a patient and provider perspective, it would be inappropriate, unsafe, and misleading to allow biosimilar products to use the same name for biological products that are not exactly the same,’ Richard Dolinar, the group’s chairman wrote in a recent Food and Drug Law Institute Policy Forum. Tracking products by National Drug Codes, as some pharmacy groups have suggested, has limitations because the numbers are not uniformly used in medical billing, and doctors and patients associate products by name, not a number, the group says.”

Read the full Inside Health Policy article here.

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!